Anti-CLD5/ CLDN5/ AWAL monoclonal antibody

Anti-CLD5/ CLDN5/ AWAL antibody for FACS & in-vivo assay

Target products collectionGo to CLDN5/CLDN5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0285-Ab-1/ GM-Tg-hg-MP0285-Ab-2Anti-Human CLDN5 monoclonal antibodyHuman
GM-Tg-rg-MP0285-Ab-1/ GM-Tg-rg-MP0285-Ab-2Anti-Rat CLDN5 monoclonal antibodyRat
GM-Tg-mg-MP0285-Ab-1/ GM-Tg-mg-MP0285-Ab-2Anti-Mouse CLDN5 monoclonal antibodyMouse
GM-Tg-cynog-MP0285-Ab-1/ GM-Tg-cynog-MP0285-Ab-2Anti-Cynomolgus/ Rhesus macaque CLDN5 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0285-Ab-1/ GM-Tg-felg-MP0285-Ab-2Anti-Feline CLDN5 monoclonal antibodyFeline
GM-Tg-cang-MP0285-Ab-1/ GM-Tg-cang-MP0285-Ab-2Anti-Canine CLDN5 monoclonal antibodyCanine
GM-Tg-bovg-MP0285-Ab-1/ GM-Tg-bovg-MP0285-Ab-2Anti-Bovine CLDN5 monoclonal antibodyBovine
GM-Tg-equg-MP0285-Ab-1/ GM-Tg-equg-MP0285-Ab-2Anti-Equine CLDN5 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0285-Ab-1/ GM-Tg-hg-MP0285-Ab-2; GM-Tg-rg-MP0285-Ab-1/ GM-Tg-rg-MP0285-Ab-2;
GM-Tg-mg-MP0285-Ab-1/ GM-Tg-mg-MP0285-Ab-2; GM-Tg-cynog-MP0285-Ab-1/ GM-Tg-cynog-MP0285-Ab-2;
GM-Tg-felg-MP0285-Ab-1/ GM-Tg-felg-MP0285-Ab-2; GM-Tg-cang-MP0285-Ab-1/ GM-Tg-cang-MP0285-Ab-2;
GM-Tg-bovg-MP0285-Ab-1/ GM-Tg-bovg-MP0285-Ab-2; GM-Tg-equg-MP0285-Ab-1/ GM-Tg-equg-MP0285-Ab-2
Products NameAnti-CLDN5 monoclonal antibody
Formatmab
Target NameCLDN5
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CLDN5 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CLD5/ CLDN5/ AWAL VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0285
    Target NameCLDN5
    Gene ID7122,12741,65131,711884,100684266,101081005,617453,102149057
    Gene Symbol and SynonymsAWAL,BEC1,CLDN5,CPETRL1,MBEC1,™DVCF,™VCF
    Uniprot AccessionO00501,Q9JKD6,Q2HJ22
    Uniprot Entry NameCLD5_HUMAN,CLD5_RAT,CLD5_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000184113
    Target ClassificationN/A

    The target: CLDN5, gene name: CLDN5, also named as AWAL, BEC1, CPETRL1, ™DVCF, ™VCF. This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets. Mutations in this gene have been found in patients with velocardiofacial syndrome. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, May 2018].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.